MEGACE ES Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Megace Es, and when can generic versions of Megace Es launch?
Megace Es is a drug marketed by Endo Operations and is included in one NDA.
The generic ingredient in MEGACE ES is megestrol acetate. There are eighteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the megestrol acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Megace Es
A generic version of MEGACE ES was approved as megestrol acetate by STRIDES PHARMA on August 8th, 1988.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MEGACE ES?
- What are the global sales for MEGACE ES?
- What is Average Wholesale Price for MEGACE ES?
Summary for MEGACE ES
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 90 |
Clinical Trials: | 35 |
Patent Applications: | 4,472 |
Drug Prices: | Drug price information for MEGACE ES |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MEGACE ES |
What excipients (inactive ingredients) are in MEGACE ES? | MEGACE ES excipients list |
DailyMed Link: | MEGACE ES at DailyMed |


Recent Clinical Trials for MEGACE ES
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 1/Phase 2 |
Sunnybrook Health Sciences Centre | Phase 1 |
Ontario Institute for Cancer Research | Phase 1 |
Paragraph IV (Patent) Challenges for MEGACE ES
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
MEGACE ES | Oral Suspension | megestrol acetate | 125 mg/mL | 021778 | 1 | 2011-04-27 |
US Patents and Regulatory Information for MEGACE ES
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endo Operations | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | AB | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MEGACE ES
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Endo Operations | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | 5,145,684 | ⤷ Try for Free |
Endo Operations | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | 9,101,549 | ⤷ Try for Free |
Endo Operations | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | 9,040,088 | ⤷ Try for Free |
Endo Operations | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | 6,592,903 | ⤷ Try for Free |
Endo Operations | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | 9,101,540 | ⤷ Try for Free |
Endo Operations | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | 7,101,576 | ⤷ Try for Free |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MEGACE ES
See the table below for patents covering MEGACE ES around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 1014792 | ⤷ Try for Free | |
Hungary | 9301917 | ⤷ Try for Free | |
Japan | 2010248220 | NANOPARTICULATE MEGESTROL FORMULATION | ⤷ Try for Free |
Portugal | 499299 | ⤷ Try for Free | |
South Korea | 101216853 | ⤷ Try for Free | |
World Intellectual Property Organization (WIPO) | 03066021 | ⤷ Try for Free | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Market Dynamics and Financial Trajectory for MEGACE ES
More… ↓